健脾温肾软坚解毒方、康艾注射液联合低剂量化疗治疗老年脾肾两虚型晚期非小细胞肺癌的临床研究  

Clinical study on Jianpi Wenshen Ruanjian Jiedu formula,Kang’ai injection and low-dose chemotherapy in the treatment of advanced non-small cell lung cancer of spleen kidney deficiency type in the elderly

作　　者：姚逸临[1] 李和根[1] 陈智伟[2] 徐蔚杰[1] 周蕾[1] 周之毅[1] 朱丽华[1] 慕晓艳[1] 刘吟絮[1] 肖凌[1] 侯宛昕 姜雪莲 YAO Yilin;LI Hegen;CHEN Zhiwei;XU Weijie;ZHOU Lei;ZHOU Zhiyi;ZHU Lihua;MU Xiaoyan;LIUYinxu;XIAO Ling;HOU Wanxin;JIANG Xuelian(National Traditional Chinese Medicine Clinical Research Base,Oncology Department,Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Oncology Department,Shanghai Chest Hospital,Shanghai 200032,China)

机构地区：[1]上海中医药大学附属龙华医院肿瘤科,国家中医临床研究基地,上海200032 [2]上海市胸科医院肿瘤科,上海200030

出　　处：《上海中医药杂志》2020年第3期67-71,共5页Shanghai Journal of Traditional Chinese Medicine

基　　金：上海市科委医学引导类(中医)科技项目(15401931200);上海市卫健委卫生行业临床研究专项(201940144)。

摘　　要：目的观察健脾温肾软坚解毒方、康艾注射液联合低剂量化疗对老年脾肾两虚型晚期非小细胞肺癌患者瘤灶、免疫功能及无进展生存期的影响。方法将80例老年脾肾两虚型晚期非小细胞肺癌患者随机分为治疗组和对照组,每组40例。对照组予常规剂量化疗,治疗组予健脾温肾软坚解毒方、康艾注射液联合低剂量化疗。化疗2个周期后,观察两组患者瘤灶、免疫功能的变化情况,随访患者的无进展生存期。结果①试验期间,对照组脱落2例,试验组无脱落,最终完成试验者78例,其中治疗组40例,对照组38例。②两组实体瘤疗效比较,差异无统计学意义(P>0.05)。③化疗1个周期与化疗前组内比较,两组血清NK、CD3^+、CD4^+、CD8^+水平差异无统计学意义(P>0.05);化疗2个周期与化疗前组内比较,治疗组血清CD8^+水平升高(P<0.05),对照组血清NK、CD3^+、CD4^+水平降低(P<0.05)。化疗1个周期后组间比较,治疗组血清CD3^+、CD4^+水平高于对照组(P<0.05);化疗2个周期后组间比较,治疗组血清NK、CD3^+、CD4^+水平高于对照组(P<0.05)。④两组患者中位无进展生存时间均为4.5个月,差异无统计学意义(P>0.05)。结论健脾温肾软坚解毒方、康艾注射液联合低剂量化疗能有效控制老年肺肾两虚型晚期非小细胞肺癌患者的瘤灶变化,并有利于稳定血清NK、CD3^+和CD4^+水平,保护患者的免疫功能。Objective To observe the combined effect of Jianpi Wenshen Ruanjian Jiedu formula,Kang’ai injection and low-dose chemotherapy on tumor focus,immune function and progression free survival(PFS)in elderly patients with advanced non-small cell lung cancer(NSCLC)of spleen kidney deficiency type.Methods Eighty elderly patients with advanced NSCLC of spleen kidney deficiency type were randomly divided into treatment group and control group,40 cases in each group.The control group was given conventional dose chemotherapy,the treatment group was given Jianpi Wenshen Ruanjian Jiedu formula,Kangai injection combined with low-dose chemotherapy.After two cycles of chemotherapy,the tumor foci and immune function of the two groups were observed,and the PFS of patients were followed up.Results(1)During the experiment,2 cases in the control group dropped out and 78 cases completed the experiment,including 40 cases in the treatment group and 38 cases in the control group.(2)After the second chemotherapy,there was no statistical difference in the composition of tumor focus evaluation between the two groups(P>0.05).(3)Both groups showed no significant difference in the serum levels of NK,CD3^+,CD4^+,CD8^+after one cycle of chemotherapy compared with those before chemotherapy(P>0.05);the level of CD8^+in the treatment group increased(P<0.05)while the level of NK,CD3^+,CD4^+in the control group decreased(P<0.05)after two cycles of chemotherapy.After one cycle of chemotherapy,the levels of CD3^+and CD4^+in the treatment group were higher than those in the control group(P<0.05);after two cycles of chemotherapy,the levels of NK,CD3^+and CD4^+in the treatment group were higher than those in the control group(P<0.05).(4)The median PFS of the two groups was 4.5 months and the difference was not statistically significant(P>0.05).Conclusion Combined use of Jianpi Wenshen Ruanjian Jiedu formula,Kang’ai injection and low-dose chemotherapy can effectively control the changes of tumor foci in the elderly patients with lung and kidney deficien

关 键 词：非小细胞肺癌 晚期 老年 低剂量化疗 中西医结合疗法 免疫 瘤灶 

分 类 号：R734.2[医药卫生—肿瘤]